Evidence map›Paper›PMID 35018864›Full record

ReviewJournal of evidence-based integrative medicine

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Tomas Koltai, Larry Fliegel

Open access · goldAbstract readReview
In one paragraph

Review in Journal of evidence-based integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. International journal of molecular sciences · 2026
    Review
  8. Review
  9. Targetable pathways for drug repurposing in gastric cancer.World journal of gastroenterology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Investigating therapeutic efficacy of silymarin on intestinal and muscular phases of trichinellosis: an experimental study.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Formulation of silymarin surface modified vesicles: In vitro characterization to cell viability assessment.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tomas KoltaiHospital del Centro Gallego de Buenos Aires, Buenos Aires, Argentina.ORCID 0000-0002-7398-5096
Larry Fliegel12357University of Alberta, Edmonton, AB, Canada.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The flavonoid silymarin extracted from the seeds of

Indexed as

COVID-19NeoplasmsSilymarinHumansSARS-CoV-2SilybinSilybum marianumSilybinSilymarinantioxidantcancerinvasionmigrationmilk thistlesilybinsilymarin

Identifiers

PMID35018864
PMCPMC8814827
OpenAlexW4206379535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.